NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
ZEPBOUND KWIKPEN (tirzepatide) by Eli Lilly and Company is g-protein-linked receptor interactions [moa]. Approved for glucose-dependent insulinotropic polypeptide receptor agonist [epc]. First approved in 2023.
Drug data last refreshed 11h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEPBOUND KWIKPEN (tirzepatide) is a subcutaneous GIP receptor agonist approved in November 2023 for chronic weight management in adults with obesity or overweight with weight-related conditions. It works by activating G-protein-linked receptors to enhance glucose-dependent insulin secretion and satiety signaling. The KWIKPEN formulation represents a device innovation on Eli Lilly's tirzepatide platform.
Growth12.9 years to LOE
Early-stage growth product with 13+ years of patent protection; teams are scaling commercial infrastructure to capture obesity market expansion.
Mechanism of Action
G-Protein-linked Receptor Interactions
Pharmacologic Class:
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Tirzepatide for Treatment of CCCA
Started Sep 2026
20 enrolled
Central Centrifugal Cicatricial Alopecia (CCCA)
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
Started Sep 2026
20 enrolled
Pouch, IlealPouches, IleoanalBowel Diseases, Inflammatory
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Started Aug 2026
224 enrolled
Obesity and Overweight
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Started Aug 2026
60 enrolled
Idiopathic Intracranial Hypertension (IIH)
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Started Jul 2026
60 enrolled
Heart Failure and Reduced Ejection FractionObesity & OverweightTirzepatide
Worked on ZEPBOUND KWIKPEN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.